In accordance to in vitro data, cross-sectional designed studies in obese human subjects support an increase in Wnt5a concentrations in NAFLD patients, although no significant association with serum sfrp5 was observed [63,85,86]. Here, SFRP5 is linked to metabolic dysfunction-associated steatotic liver disease.